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Our recent studies established essential and distinct roles
for RalA and RalB small GTPase activation in K-Ras mutant
pancreatic ductal adenocarcinoma (PDAC) cell line tumori-
gencity, invasion, andmetastasis. However, themechanism of
Ral GTPase activation in PDAC has not been determined.
There are four highly related mammalian RalGEFs (RalGDS,
Rgl1, Rgl2, and Rgl3) that can serve as Ras effectors. Whether
or not they share distinct or overlapping functions in K-Ras-
mediated growth transformation has not been explored. We
found that plasma membrane targeting to mimic persistent
Ras activation enhanced the growth-transforming activities
of RalGEFs. Unexpectedly, transforming activity did not cor-
relate directly with total cell steady-state levels of Ral activa-
tion. Next, we observed elevated Rgl2 expression in PDAC
tumor tissue and cell lines. Expression of dominant negative
Ral, which blocks RalGEF function, as well as interfering RNA
suppression of Rgl2, reduced PDAC cell line steady-state Ral
activity, growth in soft agar, and Matrigel invasion. Surpris-
ingly, the effect of Rgl2 on anchorage-independent growth
could not be rescued by constitutively activated RalA, sug-
gesting a novel Ral-independent function for Rgl2 in trans-
formation. Finally, we determined that Rgl2 and RalB both
localized to the leading edge, and this localization of RalB was
dependent on endogenous Rgl2 expression. In summary, our
observations support nonredundant roles for RalGEFs in Ras-
mediated oncogenesis and a key role for Rgl2 in Ral activation
and Ral-independent PDAC growth.
Mutational activation of the KRAS oncogene is the most
prevalent genetic alteration associated with essentially 100% of
pancreatic ductal adenocarcinomas (PDACs)3 (1). Therefore,
considerable effort has been made to develop inhibitors of
K-Ras for PDAC treatment. Currently, most of these efforts are
focused on inhibitors of K-Ras downstream effector signaling,
with numerous inhibitors of the Raf-MEK-ERK mitogen-acti-
vated protein kinase (MAPK) or phosphatidylinositol 3-kinase
(PI3K)-AKT pathway currently under clinical evaluation (2).
However, recent studies suggest that additional Ras effector
pathways may also play significant roles in Ras-mediated onco-
genesis. In particular, there is increasing evidence for the
importance of Ral guanine nucleotide exchange factors
(RalGEFs), activators of the Ral (Ras-like) small GTPases (3), in
cancer growth (4).
Ral GTPases function as GDP/GTP-regulated binary
switches that regulate extracellular stimulus-regulated signal-
ing networks that control a diversity of cellular processes,
including exocytosis, endocytosis, activation of transcription
factors, and actin cytoskeletal reorganization (4). Surprisingly,
despite their significant sequence identity (82%) and interac-
tion with a common set of effectors, the related RalA and RalB
isoforms serve very distinct functions in oncogenesis. Impor-
tantly, Chien and White (5) found that RalA is necessary for
tumor cell anchorage-independent growth, whereas RalB is
necessary for tumor but not normal cell survival. Our studies
determined that RalA but not RalB was essential for PDAC cell
line anchorage-independent growth and tumorigenic growth in
vivo (6). In contrast, RalB and, to a lesser degree, RalA were
essential for PDAC cell Matrigel invasion and lung colonymet-
astatic tumor growth in a lung colonization model. Distinct
roles for RalA and RalB have also been described in bladder (7)
and prostate (8) cancer growth. These distinct biological roles
are due, in part, to their distinct subcellular localization, with
RalA found at the plasma membrane and endosomes, whereas
RalB is found only at the plasma membrane (9). The critical
importance of subcellular localization in Ral function was also
demonstrated by our recent observation that Aurora-A phos-
phorylation of RalA resulted in relocation from the plasma
membrane to endosomes, causing a change in effector utiliza-
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tion required to promote PDAC anchorage-independent and
tumorigenic growth (10).
Despite the importance of Ral activation in cancer growth,
themechanisms by which Ral GTPases are aberrantly activated
remain poorly understood. In our analyses of PDAC tumors
and cell lines, we observed elevated levels of GTP-bound active
RalA and RalB (6, 11). At least six Ral-specific mammalian gua-
nine nucleotide exchange factors (RalGEFs) (4) and two Ral-
specific GTPase-activating proteins (RalGAPs) (12) have been
identified. The RalGEFs activate the Ral GTPases by catalyzing
the exchange of GDP for GTP, whereas the RalGAPs inactivate
Ral GTPases by increasing hydrolysis of bound GTP to GDP.
Four of the RalGEFs contain Ras association (RA) domains that
can function as Ras effectors: RalGDS, Rgl1, Rgl2/Rlf, and Rgl3
(13–16). In light of the high frequency of KRAS mutations in
PDAC, a logical hypothesis is that one or more RA domain-
containing RalGEFs are required for Ral activation in PDAC.
However, the two pleckstrin homology domain-containing
RalGEFs may also be activated, perhaps indirectly by K-Ras
activation of their phosphotidylinositol 3-kinase effectors (17).
Moreover, although no mechanism for regulation of RalGAPs
has been described, another possible mechanism of Ral activa-
tion in PDAC could involve loss of RalGAP activity, similar to
the hyperactivation of Ras due to loss of the neurofibromin
RasGAP in glioblastoma (18) and hyperactivation of Rho due to
loss of the RhoGAP DLC1 in multiple cancer types (19).
The four RA domain-containing RalGEFs share an identical
domain organization (Fig. 1). However, overall sequence iden-
tity within these domains is limited (17–33%), with very little
identity in the sequences flanking the functional domains. This
sequence divergence may result in important functional differ-
ences between the GEFs. For example, a RalGEF-independent
function of RalGDS has been described involving activation of
AKT (20). Although ectopic overexpression of activated Ras
proteins can activate the different RalGEFs in vivo (21–24),
there are currently no data implicating a specific RalGEF in
endogenous mutant KRAS-mediated growth transformation.
Mice lacking RalGDS have a deficiency in oncogenic H-Ras-
induced skin tumor formation (25). However, it is unclear
whether RalGDS is the only RalGEF expressed inmouse skin or
whether it possesses a unique function in tumorigenesis. We
found that a constitutively activated mutant of Rgl2/Rlf was
sufficient to phenocopy activated H-Ras to cause anchorage-
independent growth transformation of immortalized human
embryonic kidney (HEK-HT) cells, although whether activated
forms of other RalGEFs were also transforming was not evalu-
ated (26). Interestingly, we found that RalA and RalB were not
activated concurrently in the same PDAC cell lines (11), indi-
cating distinct mechanisms of regulation. All four family mem-
bers are widely expressed in many tissues, but their relative
abilities to activate RalA and RalB have not been investigated.
The different RalGEFs may also exhibit distinct subcellular
localization, leading to spatially distinct Ral activation and
engagement of different effector populations (27).
The essential requirement for Ral GTPase activation in
PDAC growth has stimulated our interest in evaluating candi-
date anti-Ral approaches for PDAC treatment (10, 28). Estab-
lishing a role for RalGEFs in activation of Ral GTPases in PDAC
may validate targeting mechanisms of RalGEF activation for
pharmacologic inhibition of Ral GTPases (29). In this study,
we first compared the biochemical and biological functions
of the four RA domain-containing RalGEFs and determined
that they equally activated RalA and RalB but nevertheless
exhibited widely variable plasma membrane association-de-
pendent transforming potencies. We identified Rgl2 protein
overexpression in PDAC tumors and determined that Rgl2
was essential for PDAC cell line anchorage-independent
growth and invasion in PDAC lines in vitro, in part through
a Ral-independent mechanism(s) independent of AKT acti-
vation. Finally, we demonstrated that RalB subcellular local-
ization to the plasma membrane at the leading edge was
dependent on Rgl2 expression, suggesting that RalGEFs may
also regulate spatially restricted Ral activation.
EXPERIMENTAL PROCEDURES
Cell Lines—Immortalized human embryonic kidney cells
(HEK-HT) expressing SV40 T-Ag and t-Ag as well as the cata-
lytic subunit of telomerase (hTERT) were described previously
(26). Human PDAC cell lines were obtained from ATCC or
were provided by Dr. Murray Korc (Dartmouth). To establish
stably infected polyclonal cell populations, the indicated paren-
tal cell lines were infected with retroviruses generated from the
retroviral vectors encoding the indicated proteins, followed by
selection with puromycin. To establish stably infected mass
populations for stable Rgl2 knockdown cells, PDAC lines were
infectedwith lentivirus-based vectors encoding the nonspecific
negative control or sequences designed against human Rgl2
(see below for details), followed by selection with puromycin.
Lentivirus was established by co-transfection of the pLKO.1
shRNA vectors described below with the helper plasmids
psPAX2 and pMD2.G in HEK-293T cells with the calcium
phosphate precipitation method (30).
PDAC Patient Samples—Deidentified matched normal and
tumor pancreas samples were collected from the University of
North Carolina Tissue Procurement Facility after approval by
the University of North Carolina institutional review board.
Samples were flash frozen in liquid nitrogen at the time of oper-
ation and subsequently harvested using an Nonidet P-40-based
lysis buffer with 100 phosphatase inhibitors (phosphatase
inhibitor mixtures 1 and 2; Sigma) and 1 protease inhibitor
(Complete protease inhibitor mixture tablets; Roche Applied
Science).
RalGEF Expression Vectors—The construction of the pBabe
HAII-puro Rgl2-CAAX vector was described previously (26).
Full-length, wild-type mouse RalGDS, Rgl1, Rgl2, and Rgl3
open reading frames were isolated from a mouse cDNA library
by PCR with primers to incorporate the following flanking
restriction sites: RalGDS, BamHI and EcoRI; Rgl1, BamHI and
BamHI; Rgl2 and Rgl3, EcoRI and SalI. These fragments were
then subcloned into the pBabe HAII-puro retrovirus expres-
sion vector, which adds an in-frame sequence to encode an
N-terminal hemagglutinin (HA) epitope tag sequence. In order
to add sequences to encode for the K-Ras4B C-terminal se-
quence to the C terminus of the RalGEFS, we ligated annealed
oligonucleotides representing the 20 C-terminal amino acids
of human K-ras4B and restriction site overhangs to the above
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RalGEF open reading frames in the pBabe-puro constructs.
The primers used were as follows: for RalGDS-CAAX,
Rgl1-CAAX, and Rgl3-CAAX (MluI and SalI restriction
sites), 5-CGCGTCTAAGCAAAGATGGTAAAAAGAA-
GAAAAAGAAGTCAAAGACAAAGTGTGTAATTATGT-
GAG-3 (top) and 5-TCGACTCACATAATTACACACTT-
TGTCTTTGACTTCTTTTTCTTCTTTTTACCATCTTT-
GCTTAGA-3 (bottom); for Rgl3-CAAX (MluI and MluI
restriction sites), 5-CGCGTCTAAGCAAAGATGGTAAA-
AAGAAGAAAAAGAAGTCAAAGACAAAGTGTGTAA-
TTATGTGAG-3 (top) and 5-CGCGCTCACATAATTAC-
ACACTTTGTCTTTGACTTCTTTTTCTTCTTTTTACC-
ATCTTTGCTTAGA (bottom). RalA (S31N) and RalB
(S28N) were generated by site-directed mutagenesis from
pBabe-puro RalA and RalB (11). Note that the same analo-
gous residue was mutated in both Ral isoforms, but the RalA
isoform used is a splice variant that contains three additional
N-terminal residues. A hygromycin-resistant expression
vector for RalAQ75L was constructed subcloning the cDNA
sequence from pBabe-puro-RalAQ75L (11) into the pBabe-
hygro vector. Lentiviral shRNA vectors designed to target
human Rgl2 (accession number NM_004761) in the pLKO.1
backbone were obtained from Open Biosystems. The target
sequences are as follows: RNAi 1, 5-GCAGTGTCTATAA-
GAGCATTT-3; RNAi 2, 5-CCATTCTGAATGGTGGCA-
ATT-3. The nonspecific vector is the Mission Non-Target
shRNA control vector (Sigma-Aldrich) that does not target
human genes.
Immunoblotting—Lysates were obtained from the indicated
exponentially growing cell lines and immunoblotted with
-RalA (Transduction Laboratories), -RalB (Upstate Biotech-
nology, Inc.), --actin (Sigma), 12CA5 -HA (hemagglutinin
tag; Roche Applied Science), Rgl2 (Abnova), phospho-AKT
(Ser473; Cell Signaling), AKT (Cell Signaling), phospho-ERK
(Thr202/Tyr204; Cell Signaling), ERK (Cell Signaling), and vin-
culin (Sigma) antibodies. RalA-GTP and RalB-GTP levels were
determined by pull-down with a bacterially expressed RalBP1
RalBD-GST, followed by immunoblot with the RalA or RalB
antibodies above, as described previously (31, 32).
Immunofluorescence—The stably infected HEK-HT cells or
CFPAC-I cells were plated on glass slides and 24 h later were
fixed with 4% paraformaldehyde, permeabilized with 0.2% Tri-
ton X-100. For the HEK-HT analysis, cells were incubated with
the mouse 12CA5 -HA primary antibody (Roche Applied Sci-
ence) for 1 h at room temperature, followed by the Alexa Fluor
488-conjugated -mouse secondary antibody (Molecular
Probes) for 1 h. For the endogenous Rgl2 analysis, CFPAC-I
cells were incubated with the mouse -Rgl2 primary antibody
(Abnova) for 1 h at room temperature followed by the Alexa
Fluor 488-conjugated -mouse secondary antibody (Molecular
Probes) for 1 h. For the endogenous Rlg2, RalB, and RalB anal-
ysis, cells were incubated with 1) themouse -RalA (Transduc-
tion Laboratories), 2) -Rgl2 and rabbit -cortactin (Cell Sig-
naling), or 3) -RalB and rabbit -cortactin for 1 h at room
temperature, followed by both the Alexa Fluor 488-conjugated
-mouse secondary (Molecular Probes) and the Alexa Fluor
568-conjugated -rabbit secondary antibodies (Molecular
Probes) for 1 h at room temperature. Cells were mounted with
Fluorosave (Calbiochem) and visualized with a Zeiss 510 LSM
confocal microscope. Digital images were processed and
adjusted for contrast and brightness with the LSM 5 Image
browser software (Zeiss, Thornwood, NY).
Anchorage-independent Growth Assays—Anchorage-inde-
pendent growth assays consisted of suspending cells in soft agar
as described previously (33). Briefly, cells were trypsinized, and
4  104 cells (HEK-HT) or 1  104 cells (PDAC lines) were
resuspended in growth medium containing 0.4% agar in 6-well
plates. Cells were maintained at 37 °C for 4 weeks (HEK-HT
cells) or 2 weeks (PDAC lines). After this time, viable colonies
were stained with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphen-
yl-2H-tetrazolium bromide viability stain. The total number
per plate of viable colonies of10 cellswas quantified by count-
ing the number of colonies in five representative fields of view
within each plate. Results are expressed as mean  S.D.
Invasion Assays—Invasion assays were performed with
growth factor-reducedMatrigel invasion chambers (BD Bio-
sciences) according to the manufacturer’s protocol. Briefly,
cells were dissociated from the plates with TrypLE Express
(Invitrogen), and 1  105 cells were resuspended in triplicate
in serum-free RPMI 1640 containing 1% bovine serum albu-
min into the upper chamber. RPMI 1640 containing 3% fetal
bovine serum as a chemoattractant was added to the bottom
well. Cells were allowed to invade for 22 h at 37 °C, and then
non-invaders were removed. Invading cells were fixed and
stained with the Diff-Quik stain set (Dade Behring Inc.,
Newark, DE). Five fields were counted for each chamber, and
the total number of cells counted per chamber was used for
calculating the average number of invading cells. Results are
expressed as mean  S.D.
Reverse Transcription (RT)-PCR Analysis—Total mRNAwas
extracted from the indicated PDAC cancer cell lines with an
RNeasy kit (Qiagen). RNA was quantified by measuring the
absorbance at 260 nm. cDNA libraries were then formed by
reverse transcription using a PE Applied Biosystems high
capacity cDNA archive kit. 10 g of RNA was used for the
reverse transcription in all cases. An RNase inhibitor (RNasin;
Promega) was used during the reverse transcription. Specific
primer sets were then used to amplify the respective genes by
PCR amplification. PCR amplification without cDNA was per-
formed in parallel as a negative control. Primers used were
designedwith the help of the Primer3 software (available on the
World Wide Web) and are as follows, with forward primer
followed by reverse: RalGDS, 5-GTCTCAGGGCTCTGCAA-
CTC-3 and 5-TCTTCAGCTTCCGGTCATCT-3; Rgl1, 5-
AACCACTCAGAGGCTGAGGA-3 and 5-AGACAGAGC-
GCTTGTGGATT-3; Rgl2, 5-GCCTCTGATTGCCGTAT-





Statistical Analysis—Data were analyzed using an unpaired t
test. Values are shown as means  S.D. A p value of 0.05 was
considered significant.
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RESULTS
Although our studies identified Ral activation in PDAC and
we established critical and distinct roles for RalA and RalB in
PDACcell line growth (6, 11), amechanism for Ral activation in
PDAC remains to be determined. Because mutationally acti-
vated K-Ras is found in essentially all PDACs, a logical mecha-
nism would involve one or more of the four RA domain-con-
taining RalGEFs (RalGDS, Rgl1, Rgl2, and Rgl3) that function as
effectors of Ras (Fig. 1). The demonstration that a RalGDS defi-
ciency alone impaired mutant H-Ras-induced skin carcinoma
formation suggests non-redundant roles for RA domain-con-
taining RalGEFs Ras-mediated oncogenesis (25). Therefore, we
compared the activities of the four RalGEFs. Because antibodies
were not available for recognition of all four RalGEFs, we intro-
duced an N-terminal HA epitope tag to each RalGEF to moni-
tor cellular expression.
Activated Ras promotes RalGEF activation by promoting
RalGEF association with the plasma membrane, and previous
studies showed that the addition of a Ras C-terminal plasma
membrane targeting sequence results in constitutively acti-
vated RalGDS (34), Rgl2 (24), and Rgl3 (13). These previous
studies verified that the addition of the Ras plasma membrane
targeting sequence promoted association with membranes. In
the case of RalGDS and Rgl3, highly increased membrane asso-
ciation was demonstrated by cell compartment fractionation,
and Rgl2 membrane localization was demonstrated with
microscopy.We therefore generated chimeric RalGEF proteins
that terminated with the C-terminal plasma membrane target-
ing sequence of K-Ras4B (Fig. 1). This sequence includes the
CAAX tetrapeptide motif that signals for posttranslational
modification by farnesyl isoprenoid addition aswell as the poly-
basic sequence required for plasma membrane association.
We showed previously that the RalGEF-Ral effector pathway
is necessary and sufficient for activated H-Ras growth transfor-
mation of immortalized HEK-HT human embryonic kidney
epithelial cells (26). Therefore, we utilizedHEK-HT cells to evalu-
ate the transforming activity of the four Ras-binding RalGEFs.
We established mass populations of HEK-HT cells stably
expressing wild type (WT) and membrane-targeted (desig-
nated CAAX, for cysteine, aliphatic, and terminal amino acids)
versions of each RalGEF. As a positive control, we also estab-
lished cells expressing the activated K-Ras4B(G12V) protein.
Wild-type RalGEFs Exhibit Similar Cytoplasmic Subcellular
Localization—We first compared the subcellular localization of
the wild-type RalGEFs and found that they showed similar dif-
fuse cytoplasmic localization, with a concentration in the
perinuclear region, with nuclear exclusion (Fig. 2). Additionally,
each exhibited limited and restricted plasma membrane associa-
tion.We also saw similar localizations of all four RalGEFs when
GFP-tagged versions of the wild type RalGEFs were expressed
transiently in COS-7 cells (data not shown). This subcellular
distribution is similar to the punctuate endosome localization
described previously for Rgl2 (23, 24, 26). In contrast, all of the
CAAX motif-terminating RalGEFs were localized primarily
and evenly along the plasmamembrane in the HEK cells, with a
significant loss of perinuclear staining (Fig. 2B). This distribu-
tion is similar to that seenwithK-Ras4B (35). Thus, thesemem-
brane-targeted variants are expected to mimic the activity of
authentic RalGEFs when associated with plasma membrane-
associated activated K-Ras.
Plasma Membrane-targeting Promotes RalGEF Transform-
ing Activity—We next evaluated the transforming abilities of
wild type and membrane-targeted RalGEFs using HEK-HT
cells. For these analyses, we included a previously described
constitutively activated variant of Rgl2, designated Rlf-CAAX,
which contains a similar K-Ras4B C terminus but additionally
contains a deletion of theC-terminal RAdomain (Fig. 1) (24). In
contrast to the previously used Rlf-CAAX, our constructs
retained the RA domain (Fig. 1), so that they may presumably
retain their full regulation by Ras. We found previously that
Rlf-CAAX can phenocopy activated H-Ras(12V) and promote
the anchorage-independent growth of HEK-HT cells (26).
Therefore, we utilizedHEK-HT cells to evaluate the transform-
ing activity of the four Ras-binding RalGEFs. We first verified
expression of the ectopically introduced RalGEFs by Western
blot analyses of stably infected HEK-HT cells (supplemental
Fig. 1). The expression of allWT RalGEFs was detected readily,
although Rgl2 and Rgl3 showed higher expression levels. In
contrast, although Rgl3-CAAX and Rlf-CAAX (RA) expres-
sion was also seen at comparable levels, we consistently found
very low levels of RalGDS-CAAX, Rgl1-CAAX, and Rgl2-
CAAX. Although the basis for this lower steady-state expres-
sion was not clear, it was reproducibly seen in independently
FIGURE 1. Domain structure and sequence identity of RA domain-con-
taining RalGEFs. The four RalGEFs that can serve as effectors of Ras share the
same domain topology, with an N-terminal Ras exchange motif (REM), fol-
lowed by the CDC25 homology RalGEF catalytic domain and a C-terminal RA
domain. The sequence identities to RalGDS are indicated below each domain.
The precise function of the Ras exchange motif domain is not known, but
deletion analysis of RalGDS indicates that it is dispensable for RalGEF catalytic
activity in vivo. Unlike other CDC25 homology domain-containing GEFs,
the RalGEFs are selective for the two Ral isoforms. The RA domain binds to
GTP-bound Ral. Expression vectors encoding full-length mouse RalGDS
(NM_009058), Rgl1 (NM_016846), Rgl2 (NM_009059), and Rgl3 (NM_023622)
were generated that included either N-terminal HA epitope or GFP
sequences. To generate plasma membrane-targeted versions that mimic
constitutive association with activated K-Ras, the C-terminal 20 residues of
human K-Ras4B were added to the C terminus of each RalGEF; this sequence
includes the CAAX prenylation signal sequence and the polybasic second
signal required for plasma membrane association. Rlf-CAAX contains an
N-terminal HA epitope tag (MAYPYDVPDYASTD) followed by residues 2–532
of mouse RGL2 and then 12 vector-encoded residues (HAPGRHGRGIVN) and
then terminating with 20 residues that include the K-Ras4B sequence (KMSK-
DGKKKKKKSKTKCVIM). The C-terminal 246 residues of Rlf, including the RA
domain, are deleted.
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established HEK-HT cell lines and when transiently expressed
in 293T cells (data not shown).
We then assessed the ability of the RalGEF-expressing cells
to proliferate in an anchorage-independent environment by
quantitation of colony formation in soft agar (Fig. 3). Similar to
our previous observations with activated H-Ras(12V) (26),
ectopic expression of activated K-Ras(12V) also stimulated
HEK-HT soft agar growth. As we observed previously (11, 26),
cells expressing Rlf-CAAX also showed a comparable enhance-
ment in the frequency of soft agar colony formation. In con-
trast, ectopic overexpression of each of the four WT RalGEFs
did not cause a significant increase in colony formation above
that seen for the vector control cells. However, ectopic expres-
sion of the plasma membrane-targeted versions of Rgl1, Rgl2,
and Rgl3, but not RalGDS, did promote soft agar growth.When
considered with the significantly lower level of steady-state
expression of Rgl1-CAAX and Rgl2-CAAX when compared
with their authentic counterparts, this suggests that membrane
targeting greatly enhanced Rgl1 and Rgl2 transforming activity,
whereas membrane targeting caused a moderate increase in
Rgl3 transforming activity. Because RalGDS-CAAX expression
was much lower than that of WT RalGDS, we cannot conclude
that membrane targeting did not enhance RalGDS transform-
ing activity. Finally, because the RA domain-deleted version of
Rgl2 (Rlf-CAAX) was expressed at a significantly higher steady
state level than the full-length counterpart (Rgl2-CAAX), we
suspect that deletion of the RA domain did not significantly
alter Rgl2 activity in vivo. This would also be consistentwith the
previous determination that deletion of the RA domain did not
alter Rgl2 RalGEF catalytic activity in vitro (24).
Wild-type and Activated RalGEFs Activate RalA and RalB—
Our previous finding that RalA andRalB activities variedwidely
when evaluated in PDAC cell lines suggested that the different
RalGEFs may exhibit preferential abilities to activate RalA and
RalB. This possibility was supported byRNAi suppression stud-
ies, where depletion of RalGDS caused accumulation of binu-
cleate cells as seen with RalA depletion in HeLa cells (36). In
contrast, depletion of Rgl1 caused bridged cells, as was seen
with RalB depletion in HeLa cells. No effect was seen with Rgl2
or Rgl3 depletion. To address this possibility, we did pull-down
analyses to assess RalA and RalB activation by ectopic expres-
sion of WT or membrane-targeted RalGEFs in HEK-HT cells
(supplemental Fig. 1). As expected, K-Ras(12V) cells showed
elevated RalA and RalB GTP-bound protein levels. Ectopic
overexpression of WT Rgl2 in particular caused a strong
increase in both RalA and RalB activity. A lesser increase was
seenwith Rgl3-expressing cells, whereas no significant increase
was seen for RalGDS- or Rgl1-expressing cells. Surprisingly, for
the membrane-targeted RalGEFs, only significant RalA and
RalB activation was seen with Rgl3-CAAX and Rlf-CAAX.
However, due to themuch lower expression levels of the CAAX
versions of RalGDS, Rgl, and Rgl2, it was difficult to determine
whether their inability to activate RalA and RalB was due to any
inherent differences between the GEFs. Furthermore, despite
the stronger transforming activity of Rgl2-CAAX, it showed a
reduced ability to increase Ral-GTP levels when comparedwith
WT Rgl2. Thus, we saw that the different RalGEFs did not dif-
ferentially regulate RalA andRalB activity and that the Ral-GTP
levels did not correlate with transforming activity.
FIGURE 2. RalGEFs exhibit similar cytosolic subcellular localization and
plasma membrane association is enhanced by the addition of the
K-Ras4B plasma membrane targeting sequence. A, wild type RalGEFs
exhibit a cytosolic subcellular localization. Mass populations of HEK-HT cells
were stably infected with pBabe-puro expression vectors expressing the indi-
cated HA-tagged RalGEFs and were grown on glass coverslips. After labeling
with anti-HA antibody followed by Alexa Fluor 488-conjugated secondary
antibody, the cells were visualized by confocal microscopy. Arrows, plasma
distinct plasma membrane localization. B, the addition of Ras membrane tar-
geting sequence enhances RalGEF plasma membrane association. Analyses
were done as described in A with chimeric RalGEFs terminating with the
K-Ras4B plasma membrane targeting sequence. Data shown are representa-
tive of at least two independent experiments.
FIGURE 3. Membrane association promotes RalGEF transformation of
HEK-HT cells. HEK-HT cells were suspended in soft agar as described (57), and
the number of proliferating viable colonies of 30 cells were quantitated
after 4 weeks. Data shown are the average  S.D. (error bars) of triplicate
plates and are representative of three independent experiments. *, p  0.005
versus vector control.
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Rgl2 Overexpression in PDAC Tumors—The RalGEFs are all
widely expressed in different human tissues, with RalGDS and
Rgl2 showing the widest tissue distribution (15, 37–39). Uni-
Gene analysis (see the NCBIWeb site) identified RalGDS, Rgl2,
and, to a lesser extent, Rgl1 mRNA in pancreas and pancreatic
cancer tissue (Rgl3 was not in the data base). The Oncomine
data base identified mRNA expression of all four GEFs in nor-
mal and pancreatic cancer tissue by microarray analysis (40),
although their relative abundances were not determined. Inter-
estingly, the Oncomine data base also shows that Rgl2 but not
any of the other GEFs was overexpressed in pancreatic cancer
versus normal tissue. To more directly compare the expression
levels of theRalGEFs in PDAC,we performedRT-PCR to deter-
mine the presence of mRNA of the four RalGEFs in several
PDACcell lines (Fig. 4A).We readily detected bothRalGDS and
Rgl2 mRNA in all of the PDAC lines. In contrast, Rgl1 and Rgl3
transcription was readily detected only in CFPAC-I cells. Rgl1
and Rgl3 mRNA have been detected previously in lung tissue
(15, 39). Thus, as a positive control for Rgl1 and Rgl3 expres-
sion, we also readily detected Rgl1 and Rgl3 mRNA in several
NSCLC lines (data not shown). Based on these observations
and on the transforming activity of membrane-targeted Rgl2,
we focused on Rgl2.
To determine the protein levels of Rgl2 in PDAC lines, we
have performed Western blot analysis (Fig. 4B). Consistent
with the RT-PCR analysis, we detected Rgl2 protein in all
PDAC cell lines. However, its expression level was highly vari-
able between lines.We attempted to generate rabbit antisera to
detect RalGDS, Rgl1, and Rgl3; however, these antisera were
not able to recognize endogenous proteins. We also tested var-
ious commercial RalGDS antibodies, and we could not detect
even overexpressed RalGDS in HEK-HT lysates. Therefore, we
could not perform similar analyses of endogenous RalGDS,
Rgl1, and Rgl3 protein. Additionally, we used Western blot
analyses and determined that Rgl2 protein was overexpressed
in three of the five PDAC patient samples tested when com-
pared with normal tissue (Fig. 4C), suggesting that Rgl2 expres-
sion is also elevated in PDAC cell lines.
RalGEFs Promote Ral Activation and PDAC Anchorage-
independentGrowth and Invasion throughMatrigel—Todeter-
mine if Ral activation and PDAC growth are dependent on
RalGEF function, we utilized dominant-negative mutants of Ral
that antagonize RalGEF function (41). The RalA(31N) and
RalB(28N) mutants are analogous to the Ras(17N) dominant
negative and should form nonproductive complexes with both
RA and pleckstrin homology domain RalGEFs, thus preventing
RalGEF-dependent Ral activation (42); however, they should
not impair Ral activation due to loss of RalGAP function.
Because the RalGEFs contain other domains not necessarily
involved in Ral activation, the use of dominant negatives may
block RalGEF functions besides Ral activation. For these anal-
yses, we utilized three PDAC cell lines that we determined pre-
viously to be strongly dependent on RalA and RalB function for
anchorage-independent growth and invasion throughMatrigel
(6). We established SW-1990, MIA PaCa-2, and CFPAC-I
PDAC cells stably expressing dominant-negative RalA(31N) or
RalB(28N) (Fig. 5A). First, we found that dominant negative Ral
protein expressionwas well tolerated and expressed severalfold
above endogenous Ral protein expression. Moreover, we did
not observe significant alteration in anchorage-dependent
growth on plastic. Ectopic expression of either RalA(31N) and
RalB(28N) significantly reduced the steady-state levels of both
RalA-GTP and RalB-GTP in SW-1990 and CFPAC-I cells, sug-
gesting that RalGEF activity is a key basis for Ral activation in
these two PDAC lines (Fig. 5A). In contrast, in MIA PaCA-2
cells, although RalB(28N) reduced RalB-GTP levels, RalA(31N)
expression did not significantly reduce RalA-GTP levels. Thus,
Ral activation inMIA PaCa-2 cells appears to be less dependent
on RalGEF function.
We showed previously that RalA but not RalB shRNA
reduced the anchorage-independent growth of these three
PDAC cell lines (6). Therefore, we determined if inhibition of
RalGEF function would alter the anchorage-independent
growth of PDAC cells. Expression of RalA(31N) caused a
greater than 50% reduction in soft agar colony formation for all
three cell lines, whereas expression of RalB(28N) reduced sig-
nificantly the colony formation activity of SW-1990 (80%
reduction) but resulted in no statistically significant reduction
for MIA PaCa-2 or CFPAC-I cells (Fig. 5B). These results sup-
port the critical role of RalGEFs in PDAC anchorage-indepen-
dent growth. RalB(28N) blocked total RalA-GTP levels but did
not affect CFPAC-I colony formation, whereas RalA(31N)
blocked RalA-GTP levels and anchorage-independent growth.
This might be due to spatial differences in RalA and RalB acti-
vation. Due to the different subcellular localization of RalA and
RalB (9), RalB(28N) might block a non-transforming pool of
RalA, whereas RalA(31N) blocks a transforming pool. Interest-
ingly, anchorage-independent growth of MIA PaCa-2 was
FIGURE 4. Pancreatic carcinoma cells express multiple RalGEFs. A, RT-PCR
detection of RalGEF mRNA colorectal and pancreatic ductal adenocarcinoma
cell lines, with -actin as a control. Total cellular RNA was isolated from the
indicated cell lines. After reverse transcription, PCR was performed with RalGEF-
specific and -actin-specific primers. B, Rgl2 protein expression in PDAC cell
lines. Lysates from the cell lines were separated by SDS-PAGE and transferred
to a PVDF membrane and blotted for Rgl2 protein expression. A parallel blot
for -actin was done to ensure equivalent loading of total cellular protein.
C, overexpression of Rgl2 protein in tumor (T) versus normal (N) matched
PDAC patient samples, as analyzed by Western blot analysis, with -tubulin
monoclonal antibody (Sigma) as a control for equivalent total protein.
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reduced by RalA(31N), despite RalA-GTP levels not being low-
ered, suggesting that there may be Ral-independent effects of
the RalGEFs in anchorage-independent growth.
We determined previously that RalA shRNA reduced
SW-1990 andMIA PaCa-2 invasion throughMatrigel, whereas
RalB shRNA significantly reduced invasion for all three lines
(6). RalB(28N) but not RalA(31N) expression statistically
reduced (p 0.05)MIAPaCa-2 andCFPAC-I invasive ability of
all three PDAC lines (Fig. 5C). Taken together, these results
support an important role for RalGEFs in PDAC growth and
invasion, at least in part, through Ral activation. Interestingly,
these results also suggest that there are RalGEFs that are some-
what specific for RalA or RalB activation, because in general,
RalA(31N) more strongly blocked anchorage-independent
growth, and RalB(28N) more strongly blocked invasion. How-
ever, inMIA PaCa-2 cells, there is no correlation of anchorage-
independent growth with RalA-GTP. This strongly suggests
that sequestration of the RalGEFs by dominant negatives may
be altering anchorage-independent growth and invasion by
means other than altering Ral activity. Indeed, in light of our
demonstration of RalA-independent effects of Rgl2 in anchor-
age-independent growth, it is difficult to correlate the pheno-
types of the dominant negatives directlywith reductions in total
cell steady-state RalA and RalB activity.
Rgl2 Promotes PDACRalActivation, Anchorage-independent
Growth, and Invasion through Matrigel—Because we observed
Rgl2 protein overexpression in PDACpatient samples (Fig. 4C),
we next wanted to determine if Rgl2 was important for the
RalGEF-dependent activities identified by Ral dominant nega-
tive mutant expression in SW-1990, MIA PaCa-2, and
CFPAC-I PDAC cell lines. Using two different shRNA vectors
that target different Rgl2 sequences, we established mass pop-
ulations of each PDAC cell line with stable suppression of Rgl2
protein expression (Fig. 6A). Significant reduction in both
RalA-GTP and RalB-GTP levels was seen in SW-1990 and
CFPAC-I cells (Fig. 6A), which is consistent with our Rgl2 over-
expression data that showed increased levels of both RalA and
RalB activation in HEK-HT cells (Fig. 3A). However, Rgl2
knockdown in MIA PaCa-2 cells only slightly reduced RalB-
GTP levels and did not detectably reduce RalA-GTP levels
(Fig. 6A).
Rgl2 suppression was associated with strong reduction in
both soft agar colony growth (Fig. 6B) and invasion through
Matrigel (Fig. 6C) for all three cell lines, although the anchor-
age-independent growth suppression was only statistically sig-
nificant for Rgl2 shRNA 1 in CFPAC-I cells.We concluded that
Rgl2 is essential for Ral activation in a subset of PDAC cells and
for PDAC cell anchorage-independent growth and invasion in
vitro. Because RalA and RalB activation in MIA PaCa-2 cells
is largely Rgl2-independent and there is high expression of
RalGDS, we also sought to determine whether RalGDS is cru-
cial for Ral activation in PDAC lines. However, we could not
find any antibodies that recognized endogenous or overex-
pressed RalGDS. Furthermore, using the identical method for
lentiviral shRNA knockdown, we were unable to knock down
the expression of RalGDS, as judged by RT-PCR analysis (data
not shown).
RalA-independent Effects of Rgl2 Mediate Anchorage-inde-
pendent Growth—Because knockdown of Rgl2 and expression
of a RalA dominant negative in MIA PaCa-2 cells caused
a decrease in anchorage-independent growth but did not
decrease RalA-GTP levels, we hypothesized that Rgl2 may pro-
mote MIA PaCa-2 anchorage-independent growth in part
through a RalA-independent mechanism(s). To address this
possibility, we determined whether ectopic expression of a
constitutively activated mutant of RalA (Q75L) could rescue
the effects of Rgl2 knockdown. Western blot analyses veri-
fied expression of the altered mobility form of RalA(75L) in
MIA PaCa-2 cells at a level comparable with that of endog-
FIGURE 5. Dominant negative Ral mutant inhibitors of RalGEFs impair
PDAC soft agar growth and invasion through Matrigel. A, effect on the
RalGEFs in RalA- and RalB-GTP levels in pancreatic ductal adenocarcinoma cell
lines. The indicated cell lines were stably infected with retroviral pBabe empty
vector or Ral dominant negatives (RalA(31N) and RalB(28N)) and selected
with puromycin. RalA- and RalB-GTP were detected as previously described
(29) by pull-down from the indicated PDAC lines, followed by immunoblot
analysis with the RalA or RalB antibody. Total RalA and RalB were derived from
immunoblotting total lysate and show stable expression of RalA(31N) or
RalB(28N), respectively. Blot analysis with anti--actin antibody was done to
verify equivalent total protein. B, role of the RalGEFs in PDAC anchorage-
independent growth. The number of proliferating viable colonies of 30 cells
were quantitated after 2 weeks. Data shown are the average  S.D. (error bars)
of triplicate plates and are representative of at least two independent exper-
iments. C, role of the RalGEFs in PDAC invasion. The indicated cells were dis-
sociated and resuspended in serum-free growth medium containing 1% BSA
and incubated at 37 °C in the upper chamber of a Matrigel invasion chamber.
Data shown are the percentage of invaded cells relative to vehicle and are the
average  S.D. of triplicate chambers and are representative of at least two
independent experiments. *, p  0.05 versus pBabe vector control. **, p 
0.005 versus pBabe vector control.
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enous wild type RalA (Fig. 7A). Surprisingly, activated RalA
did not rescue the anchorage-independent growth pheno-
type to the levels seen in the nonspecific shRNA control,
with only partial rescue seen (Fig. 7B). Together with our
previous studies (6, 11), these data indicate that Rgl2 pro-
motes anchorage-independent growth through RalA-depen-
dent and independent mechanisms.
Next, we determined how Rgl2 may function in a Ral-inde-
pendent manner to promote PDAC anchorage-independent
growth. One possible mechanism is suggested by Rgl2 associa-
tion with CNK, a scaffold protein that also interacts with Raf
and may facilitate ERK activation (43). Thus, depletion of Rgl2
may disrupt the ability of CNK to promote Raf signaling.
Another possible mechanism is based on the demonstrated
ability of RalGDS to activate AKT in a Ral-independentmanner
(20). To address these mechanisms, we determined if Rgl2
depletion correspondedwith reducedAKT and/or ERK activity
levels. We used Western blot analyses to determine steady-
state levels of phosphorylated and activated ERK and AKT and
found unexpectedly that neither were lowered in MIA PaCa-2
cells, although phosphorylated ERK was elevated in Rgl2
shRNAi 2 but not shRNAi 1 (Fig. 7C). These results argue
against these two possible Ral-independent signaling activities
as the basis for Rgl2 depletion-associated growth inhibition.
Rgl2 Is Localized to the Leading Edge and Its Expression Is
Required for RalB Association with the Leading Edge—An addi-
tional function of RalGEFs may be their regulation of distinct
spatial activation of their GTPase substrates (27). To further
investigate the role of Rgl2 in PDAC cells, we examined the
subcellular localization of endogenous Rgl2 in CFPAC-I cells.
To demonstrate the specificity of the Rgl2 antibody, we used
FIGURE 6. The RalGEF Rgl2 plays a crucial role in PDAC. The indicated cell
lines were stably infected with a nonspecific shRNA vector (NS), which does
target any human genes, or two independent shRNA vectors targeting Rgl2.
A, Rgl2 is responsible for RalA and RalB activation in PDAC lines. RalA- and
RalB-GTP were detected as described previously (29) by pull-down from the
indicated PDAC lines, followed by immunoblot analysis with the RalA or RalB
antibody. Total RalA and RalB were derived from immunoblotting total lysate.
Blot analysis with anti--actin antibody was done to verify equivalent total
protein. Data shown are representative of two independent experiments.
B, role of the Rgl2 in PDAC anchorage-independent growth. The number of
proliferating viable colonies of 30 cells was quantitated after 2 weeks. Data
shown are the average  S.D. (error bars) of triplicate plates and are repre-
sentative of at least two independent experiments. C, role of Rgl2 in PDAC
invasion. The indicated cells were dissociated and resuspended in serum-free
growth medium in the upper chamber of a Matrigel invasion chamber. After
22 h, the non-invaded cells were removed, and the chambers were fixed,
stained, and counted under a microscope. Data shown are the percentage of
invaded cells relative to vehicle and are the average  S.D. of triplicate cham-
bers and are representative of at least two independent experiments. *, p 
0.05 versus nonspecific shRNA control.
FIGURE 7. Activated RalA cannot rescue the anchorage-independent
growth defect of Rgl2 knockdown in MIA PaCa-2 cells. The indicated cell
lines were stably infected with a puromycin-resistant nonspecific shRNA vec-
tor (NS), which does target any human genes, or puromycin-resistant Rgl2
shRNA 1 vector targeting Rgl2, without and with ectopic expression of con-
stitutively activated RalA(Q75L). A, blot analysis showing expression levels of
endogenous wild type Rgl2 and ectopic RalA(Q75L) in the indicated PDAC
lines as well as anti-tubulin antibody to verify equivalent total protein. Data
shown are representative of two independent experiments. B, the number of
proliferating viable colonies of 30 cells was quantitated after 2 weeks. Data
shown are the average  S.D. (error bars) of triplicate plates and are repre-
sentative of at least two independent experiments. C, blot analysis demon-
strating phosphorylated and total AKT and ERK levels upon Rgl2 knockdown
in MIA PaCa-2 cells. Blot data for Rgl2 and -actin are duplicated from Fig. 6A
in this panel, where the same cell lysates were used for the AKT and ERK blot
data. Data shown are representative of two independent experiments; *, p 
0.05 between Rgl2 shRNA 1 and shRNA 1  RalAQ75L; **, p  0.005 versus
nonspecific shRNA control.
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the CFPAC-I cells stably infected with either nonspecific or
Rgl2 shRNAs as described earlier. The staining intensity was
essentially abolished in CFPAC-I cells with knockdown of Rgl2
protein (supplemental Fig. 2), indicating the specificity of the
staining. In CFPAC-I cells, Rgl2 was localized to the cytoplasm,
and a specific plasmamembrane localization was also observed
in the majority of cells (63%; Fig. 8A), consistent with previous
reports of Rgl2 localization (23, 24) and similar to the localiza-
tionwe observedwithGFP-tagged Rgl2 (data not shown). Next,
we showed that this specific membrane localization corre-
sponded to the leading edge by co-staining with cortactin, an
actin-binding protein involved in cell migration and tumor cell
invasion (44) (Fig. 8A and supplemental Fig. 3A). Previous stud-
ies have validated cortactin as a marker for the leading edge of
migrating cells (45–47). Importantly, in every cell that showed
strong membrane localization of
Rgl2, co-localization with cortactin
was also observed.
We next addressed the possibility
that Rgl2 may influence RalB sub-
cellular localization. We deter-
mined the subcellular localization
of the endogenous Ral proteins in
CFPAC-I cells and found that
endogenous RalB was localized
strongly to a specific region on the
plasma membrane and additionally
a general cytoplasmic region at the
opposite end of the cell in 50% of
cells (Fig. 8B and supplemental Fig.
3B). Next, we showed that, like Rgl2,
this plasma membrane region cor-
responded to the leading edge by co-
staining with cortactin (Fig. 8B).
Again, like Rgl2, in every case where
plasma membrane localization of
RalB was seen, this overlapped with
the localization of cortactin. This
leading edge localization of RalB is
fully consistent with the role of RalB
in migration by mobilizing the exo-
cyst complex at the leading edge
(48). Surprisingly, upon knockdown
of Rgl2, the percentage of cells
where RalB localized to the leading
edge was dramatically lowered (Fig.
8B and supplemental Fig. 3B).
Importantly, formation of the lead-
ing edge itself was not affected by
Rgl2 knockdown, because a high
percentage of cells still showed a
distinct plasma membrane localiza-
tion of cortactin upon Rgl2 deple-
tion (Fig. 8B). Because only the
active but not the total level of RalB
was lowered upon knockdown of
Rgl2 (Fig. 6A), this disappearance of
RalB from the leading edge is
explained by a redistribution away from the leading edge. We
also performed the same analysis with RalA. Endogenous RalA
localization in CFPAC-I cells was more cytoplasmic than RalB,
with leading edge localization never seen, in contrast to RalB.
Furthermore, we saw no difference in RalA localization upon
Rgl2 knockdown (supplemental Fig. 4). These results demon-
strate that RalB subcellular localization is not solely determined
by its C-terminal membrane targeting sequences but addition-
ally by association with Rgl2.
DISCUSSION
Evidence for a critical contribution of Ral GTPase activation
in human cancer cell growth continues to accumulate at a rapid
pace (4). In particular, our recent studies identified critical and
distinct roles for RalA and RalB in PDAC tumorigenic andmet-
FIGURE 8. Rgl2 expression is required for RalB association with the leading edge. A, Rgl2 is localized to the
leading edge. CFPAC-I cells were grown on glass coverslips. After labeling with mouse anti-Rgl2 and rabbit
anti-cortactin antibodies followed by Alexa Fluor 488-conjugated and 568-conjugated secondary antibodies,
cells were visualized with a confocal microscope. B, RalB localization to the leading edge is dependent on Rgl2
expression. CFPAC-I cells stably infected with either nonspecific or Rgl2 shRNA 2 were grown on glass cover-
slips. After labeling with mouse anti-RalB and rabbit anti-cortactin antibodies followed by Alexa Fluor 488-
conjugated and 568-conjugated secondary antibodies, cells were visualized with a confocal microscope. Data
shown are representative of two independent experiments. Percentages shown are percentages of 30 ran-
domly chosen cells for each experiment that demonstrate distinct plasma membrane localization for either
Rgl2, RalB, or cortactin, as shown and, in the case of the merge panel, percentages of cells that show distinct
co-localization with cortactin at the leading edge.
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astatic growth (6). However, the mechanisms by which Ral
GTPases are activated in cancer remain to be elucidated. In
light of the essentially 100% occurrence of KRAS mutations in
PDAC (1), we determined if RalGEFs that can serve as K-Ras
effectors are important mediators of Ral activation and PDAC
growth. Additionally, because there are four RalGEFs activated
by Ras, we also determined whether a specific RalGEF may be
important for PDAC growth.We found that plasmamembrane
association was sufficient to activate RalGEF transforming
potential, that all four activated RalA and RalB to comparable
levels, and that spatially distinct Ral activation may be impor-
tant for Ral-mediated growth transformation. We determined
that RalGEF activity was important for Ral activation in PDAC
cells, and in particular, Rgl2 was overexpressed in PDAC
patient tumors and was essential for the anchorage-indepen-
dent growth and Matrigel invasion of PDAC cell lines and for
Ral activation in two of three PDAC lines.
Our results provide further support for the importance of
spatial activation of Ral in promoting growth transformation.
We found that all four RalGEFs exhibited a similar subcellular
localization and were found predominantly in the cytoplasm
with a concentration in the perinuclear region and to a lesser
extent at distinct plasma membrane regions in what appear to
be ruffles in cells lacking mutant Ras. As expected, plasma
membrane targeting to mimic persistent association with
membrane-bound K-Ras enhanced RalGEF plasma membrane
association and transforming activity. However, unexpectedly,
we did not find a direct correlation between the up-regulation
of steady state Ral-GTP levels and transforming activity forwild
type or membrane-targeted RalGEFs, although we observed
previously that knockdown of RalA impaired Rgl2-CAAX-in-
duced transformation (11). This was seen strikingly for Rgl2,
where the membrane-associated form showed the same trans-
forming potency as activated K-Ras; in contrast, wild type Rgl2
was not transforming yet did cause a significant increase in
Ral-GTP levels. Thus, we show that despite being necessary for
transformation inHEK-HT cells, activation of RalA alone is not
sufficient for transformation and that differential localization
of Ral activation may contribute to different biological effects.
We suggest that the local activation of Ral at the plasma mem-
brane, rather than the increase in total cell Ral-GTP, may be
more critical to promote growth transformation. Alternatively,
another possible interpretation is that RalGEFs can promote
transformation via routes other than RalA activation, which is
fully consistent with our data in the MIA PaCa-2 PDAC cell
line, where expression of an activated RalA alone did not fully
rescue the reduced anchorage-independent growth phenotype
caused by Rgl2 knockdown (Fig. 7).
Interestingly, only the overexpression of wild-type Rgl2 and
not the other wild-type RalGEFs in HEK-HT cells significantly
activated both RalA and RalB. This result is consistent with our
observation of the necessity of endogenous Rgl2 for the full
activation of RalA and RalB in PDAC lines. This is especially
important given that other RalGEFs, such as RAlGDS, are
expressed in these PDAC lines. despite the expression of other
RalGEFs, such as RalGDS. It is certainly possible that Rgl2 has
higher intrinsic GEF activity than the other RalGEFs. Alterna-
tively, although similar to the other RalGEFs in localization, a
subtly different perinuclear or plasma membrane localization
of Rgl2 compared with the others may result in more potent
RalA and RalB activation. Taking together the observed over-
expression of Rgl2 in PDAC patient samples, our demonstra-
tion that Rgl2 overexpression in HEK-HT cells causes strong
RalA andRalB activation, and our observation that Rgl2 expres-
sion is necessary for full Ral activation in PDAC lines leads to a
model in which Rgl2 overexpression leads to a pathological
activation of RalA and RalB in pancreatic cancer.
Our observations that dominant negative Ral reduced Ral
activation levels and PDAC anchorage-independent growth
and Matrigel invasion support the importance of RalGEF acti-
vation, rather than RalGAP inactivation, for Ral activation in
PDAC, at least in SW-1990 and CFPAC-I cells. However, the
Ral dominant negative mutants are likely to block all RalGEFs,
including those not known to be regulated by Ras (RalGPS1 and
RalGPS2), so this approach did not establish the importance of
an individual RalGEF(s). However, we did note that the RalA
dominant negative preferentially impaired PDAC anchorage-
independent growth, whereas the RalB dominant negative was
more effective at blocking Matrigel invasion, consistent with
the respective roles of RalA and RalB activity in these two
PDAC growth properties (6). Thus, perhaps due to their dis-
tinct subcellular locations (9), each dominant negative mutant
selectively impaired only a subset of RalGEF activities. Never-
theless, our finding that one RalGEF, Rgl2, is elevated in expres-
sion in PDAC tumors and cell lines and that suppression of Rgl2
alone was sufficient to reduce Ral activation in a subset of
PDAC lines and to reduce PDAC growth in all lines demon-
strates the critical role of one RalGEF in PDAC cells.
Our observation that suppression of Rgl2 alonewas sufficient
to suppress Ral activation in a subset of the PDAC lines that
express additional RalGEFs was unexpected and suggests non-
redundant roles for RalGEFs in promoting Ral activation in
PDAC tumor cells.However, this is consistentwith studieswith
other Ras effectors. For example, althoughRas can interactwith
multiple isoforms of the p110 catalytic subunit of PI3K (, , ,
and ), the inability of mutant Ras to interact with only p110
was sufficient to completely suppress H-Ras-induced skin car-
cinoma formation and K-Ras-induced lung carcinoma growth
(49). That p110 is the key isoform for PI3K activation in can-
cer is also supported by the fact that only p110 is mutated in
human cancers (50). Similarly, suppression of c-Raf-1 but not
B-Raf reduced ERK activation inNRASmutantmelanoma cells,
indicating that the c-Raf-1 isoform is the critical link to ERK
activation (51).
A potential difference with individual RalGEF functions in
cancer could lie in different expression levels. Consistent with
this hypothesis, we demonstrated that at the mRNA level, only
RalGDS and Rgl2 are expressed to detectable levels in PDAC
lines, with only CFPAC-I cells, which express all four, as the
exception. This is consistent with the ubiquitous expression of
RalGDS and Rgl2, whereas Rgl1 and Rgl3 are more tissue-re-
stricted (15, 37–39). Likewise, all PDAC lines tested expressed
both RalGDS and Rgl2 protein. However, knockdown of Rgl2
specifically caused a large decrease in RalA and RalB activation
as well as their associated phenotypes of anchorage-indepen-
dent growth and invasion, respectively. Thus, the remaining
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presence of RalGDS in SW-1990 and MIA PaCa-2 cells and
RalGDS, Rgl1, and Rgl3 in CFPAC-I cells cannot functionally
compensate for the loss of Rgl2, suggesting that the RalGEFs
have distinct functions in human cancer. Intriguingly, RalGDS
knock-out in mice reduced the incidence and size of oncogenic
H-Ras-induced skin tumors (25). Thus, the question arises as to
why RalGDS is crucial in skin tumors but Rgl2 is crucial in
PDAC.One potential explanation could lie in expression levels,
such as the possibility that RalGDS is the only RalGEF highly
expressed inmouse skin. Alternatively, this may reflect Ras iso-
form differences, where RalGDS is preferentially activated by
H-Ras.
Another explanation for the crucial role of Rgl2 in PDAC
transformation is isoform-specific Ral-independent functions,
because Rgl2 has been shown to interact with the Ras scaffold-
ing protein CNK (43), whereas RalGDS interacts with PDK1 to
promote AKT activation (20, 52). In line with this hypothesis is
our observations that Rgl2 knockdown and RalA31N expres-
sion strongly suppressed anchorage-independent growth in
MIA PaCa-2 without suppression of RalA activity and that in
MIA PaCa-2 cells, activated RalA was not able to rescue the
anchorage-independent growth phenotype of Rgl2 knock-
down. These results are consistent RalA-independent effects of
Rgl2 that are necessary for anchorage-independent growth pro-
motion in PDAC. This result also provides an explanation for
why RalA(31N) blocked anchorage-independent growth in
MIA PaCa-2 cells without lowering RalA-GTP: sequestration
of Rgl2, which has RalA-independent functions in anchorage-
independent growth. It is possible that knockdown of Rgl2 does
not lower RalA-GTP sufficiently to cause the RalA-dependent
block in anchorage-independent growth seen when RalA is
knocked down (6). Becausewe demonstrated that Rgl2 does not
activate AKT or ERK, two of the other major downstream Ras
effectors, themechanism for the promotion of anchorage-inde-
pendent growth by RalA will require further investigation.
There are perhaps unknown binding partners of Rgl2 that
mediate a Ral-independent scaffolding function.
In addition to establishing a critical role for Rgl2 in Ral acti-
vation in PDAC, we demonstrated that this RalGEF may also
dictate a distinct spatial distribution of Ral activation in the cell.
Although we could not perform co-localization of Rgl2 and
RalB (due to the antibodies both being of mouse origin), our
observation that both co-localize with cortactin strongly sug-
gest that Rgl2 and RalB are co-localized at the leading edge.
Thus, Rgl2 may activate RalB by recruiting to and activating
RalB at the leading edge. RalB can then recruit and assemble the
exocyst complex to the leading edge, which is necessary for
directional motility (48). This may be partially responsible for
the invasion defect we saw upon knockdown of Rgl2. However,
further work is needed to determine the mechanism of the
demonstrated role of Rgl2 in invasion.
RalA, in contrast to RalB, did not localize to the leading edge.
Likewise, unlike RalB, expression of Rgl2 did not alter RalA
localization, although Rgl2 expression was responsible for the
full activity of both RalA and RalB. We speculate that an inter-
nal pool of Rgl2 is responsible for the activation of RalA directly
without changing its localization, whereas a leading edge pool
of Rgl2 activates RalB directly and indirectly through altering its
localization. Therefore, the distinct subcellular localization
patterns of the four Ras proteins, as well as the distinct localiza-
tion patterns of the different RalGEFs, together with the dis-
tinct subcellular localization of Rgl2 as well as RalA and RalB,
provide multiple mechanisms to modulate the spatial diversity
of activated Ral engagement of effectors in response to different
upstream stimuli and signaling components.
In summary, our studies implicate a key role for RalGEFs, in
particular Rgl2, in promoting Ral activation and PDAC growth.
Presently, we have identified and are pursuing two indirect
approaches to block Ral function for cancer treatment. First, we
have shown that inhibitors of geranylgeranyltransferase-I cause
PDAC cell growth inhibition and apoptosis, in part, by blocking
RalA and RalB function (28). However, because there are more
than 50 other substrates for this prenylation enzyme (53),
including key Rho family small GTPases, this approach is obvi-
ously limited by considerable non-Ral activities. A second
approach for a RalA-selective inhibitor is Aurora-A protein
kinase inhibitors, becausewe found that phosphorylation of the
Aurora-A site in RalA is essential for PDAC tumorigenic
growth (10). However, these inhibitors will also block the func-
tion of Aurora-A in mitosis and additionally the function of
other Aurora-A substrates (54). Thus, more selective
approaches for blocking Ral are desired. Although GEFs may
not be considered to be “druggable” targets for drug discovery,
there is increasing evidence that GEFs may be tractable for
small molecule inhibitor development (55, 56), and hence,
there is increasing interest in developing such inhibitors (29).
However, our demonstration that there are Ral-independent
effects of Rgl2 suggests that inhibiting the GEF activity alone
will not be sufficient for blocking the function of Rgl2 in PDAC
growth. Elucidating how RalGEFs are regulated by mutant
K-Ras may provide clues for the development of ways to block
RalGEF function in cancer.
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